Inflammatory Bowel Disease

WILMINGTON, Del., April 2, 2026 Earendil Labs, an AI-driven biotechnology company, has announced that the first patient has been...

CAMBRIDGE, MASSACHUSETTS, March 24, 2026 Quotient Therapeutics has announced a multi-year research collaboration with Merck & Co. to discover...

STOCKHOLM, Sweden, Feb. 21, 2026 — Johnson & Johnson announced new long-term findings from the QUASAR long-term extension study...

REYKJAVIK, Iceland, Feb. 5, 2026 —Alvotech announced positive top-line results from a pivotal pharmacokinetic (PK) study evaluating AVT80, its...

Phoenix, AZ | October 27, 2025 – Johnson & Johnson’s TREMFYA® (guselkumab) becomes the first and only IL-23 inhibitor...